XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2022
Feb. 22, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-33137    
Entity Registrant Name EMERGENT BIOSOLUTIONS INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 14-1902018    
Entity Address, Address Line One 400 Professional Drive, Suite 400    
Entity Address, City or Town Gaithersburg,    
Entity Address, State or Province MD    
Entity Address, Postal Zip Code 20879    
City Area Code 240    
Local Phone Number 631-3200    
Title of 12(b) Security Common stock, $0.001 par value per share    
Trading Symbol EBS    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status No    
Entity Interactive Data Current No    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 1.5
Entity Common Stock, Shares Outstanding (in shares)   50,140,158  
Documents Incorporated by Reference
Portions of the registrant's definitive proxy statement for its 2023 annual meeting of stockholders, which was filed with the Securities and Exchange Commission not later than 120 days after the end of the registrant's fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the registrant's definitive proxy statement for its 2023 annual meeting of stockholders that are expressly incorporated by reference into this Annual Report on Form 10-K, such proxy statement shall not be deemed filed as part of this Annual Report on Form 10-K.
    
Entity Central Index Key 0001367644    
Amendment Flag true    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Description Emergent BioSolutions Inc. (“Emergent,” the “Company,” “we,” “us,” and “our”) is filing this Amendment No. 1 (this “Amendment") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was originally filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2023 (the “Original Form 10-K”) to make certain changes as described below.As part of the Company’s quarterly review process related to the preparation of its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023, the Company determined that its net state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the income tax benefits reflected on the Company’s consolidated statement of operations. This material error was associated with the use of incorrect state tax rates in the calculation of state deferred tax assets and related valuation allowances, which are non-cash items that resulted in an understatement of the Company's income tax benefit of $11.7 million for the year ended December 31, 2022. Because the correction of this misstatement is material to the previously reported results of operations of the Company included in the Original Form 10-K, the Audit and Finance Committee of the board of directors of the Company (the “Audit Committee”) concluded that the consolidated financial statements included in the Original Form 10-K should no longer be relied upon. In connection with the restatement to correct for this error, the Company determined that it is appropriate to revise the financial statements included in the Amendment to correct other unrelated errors that were either unrecorded or addressed as out-of-period adjustments in previously filed financial statements that were not material, individually or in the aggregate, to those financial statements.Due to the discovery of this error, Company management re-evaluated the effectiveness of the Company's internal control over financial reporting (“ICFR”) as of December 31, 2022 and identified a material weakness in the Company's ICFR that existed as of December 31, 2022, relating to the calculation and review of the Company’s net state deferred tax liability. The Company’s independent registered public accounting firm, Ernst & Young LLP, has also restated its opinion on the Company’s ICFR as of December 31, 2022 to reflect this material weakness. Pursuant to this Amendment, the disclosures appearing in the Original Form10-K under the following headings are hereby deleted in their entireties and replaced with the disclosures under the following headings included herein:•Cautionary Note Regarding Forward-Looking Statements;•Part I, Item 1A - Risk Factors;•Part I, Item 2 - Properties;•Part I, Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations;•Part II, Item 8 - Financial Statements and Supplementary Data;•Part II, Item 9A - Controls and Procedures; and •Part IV, Item 15 - Exhibits and Financial Statement Schedules.In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is also including with this Amendment new currently dated certifications of the Company’s Interim Chief Executive Officer and Chief Financial Officer (attached as Exhibits 31.1, 31.2, 32.1, and 32.2). This Amendment also contains a new consent of Ernst & Young LLP attached as Exhibit 23.Except as described above, this Amendment does not amend, update or change any other items or disclosures in the Original Form 10-K and does not purport to reflect any information or events subsequent to the filing thereof. As such, this Amendment speaks only as of the date the Original Form 10-K was filed, and the Company has not undertaken herein to amend, supplement or update any information contained in the Original Form 10-K to give effect to any subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K and any subsequent filings by the Company with the SEC.